Cell line · CVCL_1776
TYK-nu
Cancer cell line, Homo sapiens. High grade ovarian serous adenocarcinoma. 35 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. TYK-nu. Cell lines, record CVCL_1776. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1776
On this page
Cell line
As Cellosaurus gives it.
- Name
- TYK-nu
- Accession
- CVCL_1776
- RRID
- RRID:CVCL_1776
- Synonyms
- TYK-NU, TYKnu, TYKNU
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 38Y
- Category
- Cancer cell line
- Diseases
- High grade ovarian serous adenocarcinoma (NCIt C105555)
- Entry created
- 2012-04-04
- Entry updated
- 2025-11-27
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers35
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| A chemoresistance-associated proliferation gene signature identified by single-cell and machine learning analysis predicts prognosis in high-grade serous ovarian carcinoma. | Transl Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Characterization of CLSP-1025, a First-in-Class, Mutation-Specific T-Cell Engager Targeting a Neoantigen Derived from a Common p53 Mutation. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Proteomic analysis of malignant ascites and its impact on ovarian cancer spheroids. | Clin Proteomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Repurposing of ivacaftor shows potential to treat ROR1 expressing high-grade serous ovarian cancer. | Ther Adv Med Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PLK1 or WEE1 inhibition targets homologous recombination repair proficiency in BRCA1/2 wild-type high-grade serous ovarian cancer. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Systematic profiling of cancer-fibroblast interactions reveals drug combinations in ovarian cancer. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. | NPJ Precis Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed |
1 to 10 of 35
See all 35 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| Derived from it | TYK-nu.CP-r | CVCL_3221 |
Source Cell lines
Cell banks1
| Cell bank | Catalog number | Status |
|---|---|---|
| JCRB | JCRB0234.0 |
Source JCRB
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1776
GET https://conductscience.org/api/cell-lines/v1/CVCL_1776/papers?page=2